文献速递呼吸衰竭与机械通气复苏、休克与脓毒症重症综合管理与镇静镇痛

COVID-19 急诊临床更新:气道管理与复苏

Clinical update on COVID-19 for the emergency clinician: Airway and resuscitation.
PubMed 文献 · Am J Emerg Med · 2022-05-14
一句话结论COVID-19 合并脓毒症休克用平衡晶体液复苏,液体无效加去甲肾上腺素,严重/难治性休克用应激剂量激素;ARDS 不延迟插管,稳定者首选HFNC/NIPPV,清醒俯卧位可降低插管率。

本文为叙述性综述,面向急诊临床医生更新 COVID-19 患者的气道管理与复苏策略。COVID-19 合并脓毒症休克应使用缓冲/平衡晶体液复苏,液体后仍低血压者启动去甲肾上腺素等血管活性药,严重或难治性脓毒症休克推荐应激剂量激素。气道管理是初始复苏的核心,COVID-19 ARDS 按非 COVID-19 ARDS 原则处理,有指征不延迟插管;临床较稳定者可随氧合需求升级采取阶梯式策略,HFNC 和 NIPPV 优先于择期插管。清醒俯卧位可降低插管率、改善氧合,采用 ARDSnet 策略目标潮气量 4-8 mL/kg 预测体重、平台压 <30 cm H2O;神经肌肉阻滞剂、肺复张、吸入肺血管扩张剂和 ECMO 证据有限。

要点

  • COVID-19 合并脓毒症休克使用缓冲/平衡晶体液复苏;液体后仍低血压启动包括去甲肾上腺素在内的血管活性药。
  • 严重或难治性脓毒症休克推荐应激剂量激素。
  • 有插管指征不应延迟;临床较稳定者可随氧合需求升级采取阶梯式策略。
  • HFNC 和 NIPPV 推荐优先于择期插管;清醒俯卧位可降低插管率、改善氧合。
  • ARDSnet 策略目标潮气量 4-8 mL/kg 预测体重、平台压 <30 cm H2O;神经肌肉阻滞剂、肺复张、吸入肺血管扩张剂和 ECMO 证据有限。

适用人群与场景

  • 急诊科 COVID-19 患者,包括脓毒症休克、ARDS 及需要气道管理与复苏者。
  • 临床较稳定、氧合需求逐步升级者可考虑阶梯式呼吸支持。

处置流程与药物剂量

  • COVID-19 合并脓毒症休克:使用缓冲/平衡晶体液复苏。
  • 液体复苏后仍存在低血压:启动包括去甲肾上腺素在内的血管活性药。
  • 严重或难治性脓毒症休克:推荐应激剂量激素。
  • 气道管理是初始复苏的核心;有插管指征不应延迟。
  • 临床较稳定的患者:可随氧合需求升级采取阶梯式策略,HFNC 和 NIPPV 推荐优先于择期插管。
  • 清醒患者可行俯卧位,已显示降低插管率并改善氧合。
  • 采用 ARDSnet 策略:目标潮气量 4-8 mL/kg 预测体重,目标平台压 <30 cm H2O。

研究设计与关键结果

  • 叙述性综述,面向急诊临床医生,聚焦 COVID-19 患者的气道管理与复苏更新。
  • COVID-19 ARDS 应按非 COVID-19 ARDS 患者同样管理。
  • 神经肌肉阻滞剂、肺复张、吸入肺血管扩张剂和 ECMO 的支持数据有限。

证据类型、等级与局限

  • 证据类型:叙述性综述。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 急诊对 COVID-19 脓毒症休克首选缓冲/平衡晶体液,液体无效时加用去甲肾上腺素等血管活性药。
  • 严重或难治性脓毒症休克考虑应激剂量激素。
  • 有插管指征时不因 COVID-19 而延迟插管;较稳定患者可先试用 HFNC 或 NIPPV,并可行清醒俯卧位。
  • COVID-19 ARDS 按 ARDSnet 策略管理,目标潮气量 4-8 mL/kg 预测体重、平台压 <30 cm H2O。
  • 神经肌肉阻滞剂、肺复张、吸入肺血管扩张剂和 ECMO 因数据有限,不作为常规推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Coronavirus disease of 2019 (COVID-19) has resulted in millions of cases worldwide. As the pandemic has progressed, the understanding of this disease has evolved.

OBJECTIVE: This narrative review provides emergency clinicians with a focused update of the resuscitation and airway management of COVID-19.

DISCUSSION: Patients with COVID-19 and septic shock should be resuscitated with buffered/balanced crystalloids. If hypotension is present despite intravenous fluids, vasopressors including norepinephrine should be initiated. Stress dose steroids are recommended for patients with severe or refractory septic shock. Airway management is the mainstay of initial resuscitation in patients with COVID-19. Patients with COVID-19 and ARDS should be managed similarly to those ARDS patients without COVID-19. Clinicians should not delay intubation if indicated. In patients who are more clinically stable, physicians can consider a step-wise approach as patients' oxygenation needs escalate. High-flow nasal cannula (HFNC) and non-invasive positive pressure ventilation (NIPPV) are recommended over elective intubation. Prone positioning, even in awake patients, has been shown to lower intubation rates and improve oxygenation. Strategies consistent with ARDSnet can be implemented in this patient population, with a goal tidal volume of 4-8 mL/kg of predicted body weight and targeted plateau pressures <30 cm H2O. Limited data support the use of neuromuscular blocking agents (NBMA), recruitment maneuvers, inhaled pulmonary vasodilators, and extracorporeal membrane oxygenation (ECMO).

CONCLUSION: This review presents a concise update of the resuscitation strategies and airway management techniques in patients with COVID-19 for emergency medicine clinicians.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Chavez S, Brady WJ, Gottlieb M, et al. Clinical update on COVID-19 for the emergency clinician: Airway and resuscitation. Am J Emerg Med. 2022. PMID: 35636042. doi:10.1016/j.ajem.2022.05.011

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。